Trials / Not Yet Recruiting
Not Yet RecruitingNCT07430267
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion: The ACE-DOUBLE Trial
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- The Alfred · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to discover if routine 'double tap' balloon post-dilation improves valve expansion and clinical outcomes in adults undergoing Transcatheter Aortic Valve Implantation (TAVI) with the SAPIEN balloon-expandable TAVI prosthesis. The primary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve expansion. The secondary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve haemodynamic performance. Participants will be randomised to balloon-expandable TAVI either with or without routine 'double tap' balloon post-dilation.
Detailed description
The ACE-DOUBLE trial will be a multicentre, registry nested, block randomized, open label clinical trial comparing routine versus discretionary balloon post-dilation strategies following TAVI using the SAPIEN 3 balloon-expandable THV for severe aortic stenosis (AS). Patients with severe symptomatic aortic valve disease that are accepted for TAVI using a balloon-expandable THV. Currently, the only balloon-expandable THV in routine clinical practice in Australia are the Sapien 3 Ultra and Sapien 3 Ultra Resilia (Edwards Lifesciences, Irvine CA, USA). Patients will be recruited from three TAVI centres participating in the ACE registry: The Alfred Hospital, Cabrini Hospital and Epworth Hospital are all located in Melbourne, Australia. Specific sub-groups may benefit more from balloon post-dilation (BPD), and hence exploratory analyses will be performed to examine the effect of BPD on primary endpoints in the following subgroups: * Male vs Female * Pre-dilation vs no pre-dilation * Tricuspid vs bicuspid aortic valve * Very severe AS (mean pressure gradient \> 50mmHg) * Very aortic valve high calcium score (\>3000 in males, \>1900 in females)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 'Double tap' balloon post-dilation | Routine second inflation of the valve delivery balloon ('double-tap') BPD following balloon-expandable valve TAVI |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-04-01
- Completion
- 2029-04-01
- First posted
- 2026-02-24
- Last updated
- 2026-02-24
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT07430267. Inclusion in this directory is not an endorsement.